NCT02609503View on ClinicalTrials.gov

Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

December 23, 2019

Study Completion Date

November 20, 2023

Conditions
Head and Neck Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable

RADIATION

Intensity Modulated Radiation Therapy

Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks

Trial Locations (3)

19111

Fox Chase Cancer Center, Philadelphia

21231

John Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT02609503 - Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin | Biotech Hunter | Biotech Hunter